Presentation TCT 2018 How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel? Presenter: John A. Bittl, C. Michael Gibson, Dimitrios Alexopoulos September 23, 2018
Presentation TCT 2018 TROPICAL-ACS: Platelet Reactivity and Clinical Outcomes in Acute Coronary Syndrome Patients Treated With Prasugrel and Clopidogrel Presenter: Jonathan M. Hill, E. Magnus Ohman, Dániel Aradi September 22, 2018
Presentation AHA 2017 One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study Presenter: Zuzana Motovska November 11, 2017
Presentation TCT 2017 Reduction of In-stent Thrombus Immediately After PCI by Pretreatment With Prasugrel Assessed by OCT Presenter: Takeshi Kimura, Shigeru Saito, Takashi Kubo October 29, 2017
Presentation TCT 2017 Dose Adjustment of Prasugrel for PCI for Japanese Patient Presenter: Takeshi Kimura, Shigeru Saito, Masato Nakamura October 29, 2017
Presentation Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS August 04, 2017
Presentation EuroPCR 2017 Prasugrel, Ticagrelor and Clopidogrel in PPCI for STEMI: An Analysis of Comparative Clinical Outcomes from the UK BCIS National Registry Presenter: Mamas A. Mamas May 22, 2017
Presentation TCT 2016 If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson October 30, 2016
Presentation ESC 2016 PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI Presenter: Zuzana Motovska August 30, 2016
Presentation ESC 2016 ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications Presenter: Gilles Montalescot August 28, 2016
Presentation CRUSH: Crushed Prasugrel Tablets in STEMI Patients Undergoing Primary PCI Presenter: Fabiana Rollini March 28, 2016
Presentation TCT 2015 TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study Presenter: Steven R. Bailey, Patrick W. Serruys, Renato Valenti October 15, 2015
Presentation TCT 2015 Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good! Presenter: Eric Boersma, E. Magnus Ohman, Giuseppe Biondi-Zoccai October 12, 2015
Presentation TCT 2015 Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit! Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo October 11, 2015
Presentation TCT 2015 Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks! Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser October 11, 2015
Presentation TCT 2015 Lessons From the TAXUS Liberté/Prasugrel Substudy Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee October 11, 2015
Presentation TCT 2015 Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)! Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh October 11, 2015
Presentation TCT 2015 Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best! Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber October 11, 2015
Presentation RECLOSE-3: Prasugrel in Clopidogrel Nonresponders Undergoing PCI Presenter: R. Valenti September 17, 2015
Presentation Predictors of Bleeding in ACS Patients Treated With Prasugrel Presenter: P. Widimsky June 19, 2015